Journals / Türk Jinekoloji ve Obstetrik Derneği Dergisi / 2013 / Cilt: 10 - Sayı: 3

COMPARISON OF MICRODOSE GnRH AGONIST PROTOCOL WITH GnRH ANTAGONIST/LETRAZOLE PROTOCOL IN PATIENTS WITH POOR OVARIAN RESPONSE

ZAYIF OVER YANITLI HASTALARDA MİKRODOZ GnRH AGONİST PROTOKOL İLE GnRH ANTAGONİST/LETRAZOL PROTOKOLUN KARfiILAfiTIRILMASI

Pages
132–137
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

While no cases of cycle cancellation was detected in the MDL group, statistically significantly higher rates of cycle cancellation (%35.7, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To compare microdose GnRH agonist (MDL) protocol with GnRH antagonist/letrazole (AL) protocol in patients with poor ovarian response.
📊
Key Findings & Data:Interventions: POR was diagnosed according to ESHRE Bologna criteria in case of presence of 2 out of 3 criteria.
💡
Conclusion & Impact:While no cases of cycle cancellation was detected in the MDL group, statistically significantly higher rates of cycle cancellation (%35.7, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To compare microdose GnRH agonist (MDL) protocol with GnRH antagonist/letrazole (AL) protocol in patients with poor ovarian response. Design: Randomised clinical trial. Setting: Kocaeli University Assisted Reproductive Centre. Patients: Fifty-five patients with the diagnosis of poor ovarian response (POR) were randomized and performed either MDL or AL protocol. Interventions: POR was diagnosed according to ESHRE Bologna criteria in case of presence of 2 out of 3 criteria. In the MDL group (n=27), 40µg/0.2 cc subcutaneous leuprolid acetate was given two times a day starting on the first day of menstrual cycle. On the second day of the cycle, gonadotrophin stimulation was started at 450-600 IU and/or 150 IU human menopausal gonadotrophin (hMG) along with leuprolid. In the AL group (n=28), 5 mg letrazole was given for 5 days starting on the second day of the spontaneous cycle and after the 5th day of the cycle, 450-600 IU and/or 150 IU hMG was given. Main Outcome Measures: To compare the outcomes of MDL protocol with AL protocol in patients with poor ovarian response. Results: Stimulation days, total gonadotrophin dose (IU), peak E2 (pg/ml) levels, and endometrial thickness were found to be statistically significantly lower in the AL group. While no cases of cycle cancellation was detected in the MDL group, statistically significantly higher rates of cycle cancellation (%35.7, p

Özet

Objektif: Zayıf over yanıtlı hastalarda mikrodoz GnRH agonist (MDL) protokol ile GnRH antagonist/letrazol (AL) protokolunun karflılafltırılması. Planlama: Randomize klinik çalıflma. Ortam: Kocaeli Üniversitesi Tıp Fakültesi Yardımla Üreme Merkezi. Hastalar: Zayıf over yanıtı (ZOY) tanısı konulan toplam 55 hasta rastgele randomize edilerek MDL ya da AL protokolu uygulandı. Giriflim: ZOY, ESHRE Bologna kriterlerine göre üç kriterden ikisinin mevcut olması halinde konuldu. MDL grubunda (n=27) siklusun birinci gününde 40µg/0.2 cc subkutan leuprolid asetat günde iki kez uygulandı. Siklus 2. gününde gonadotropin stimulasyonu 450-600 IU ve/veya 150 IU insan menapozal gonadotropin (hMG) leuprolid ile efl zamanlı uygulandı. AL grubunda (n=28) spontan menstruasyonun 2. gününde 5 mg letrazol 5 gün süre ile ve siklusun 5. gününden itibaren gonadotropin stimulasyonu 450-600 IU ve/veya 150 IU hMG uygulandı. Değerlendirme Parametreleri: Zayıf over yanıtlı hastalarda mikrodoz GnRH agonist (MDL) protokol ile GnRH antagonist/letrazol (AL) protokolunun sonuçlarını karflılafltırmak. Sonuç: Stimulasyon süresi, toplam gonadotropin dozu (IU), pik E2 (pg/ml) ve OPU günü endometrial kalınlık AL grubunda istatistiksel anlamlı olarak daha düflük saptandı. MDL grubunda siklus iptali belirlenmezken, AL grubunda istatistiksel anlamlı olarak daha fazla oranda (%35.7, p

🔖

Cite This Article

KÖPÜK, Ş. Y., VURAL, B., FİLİZ, S., ÇAKIROĞLU, Y., BAŞARIR, O. (2022). COMPARISON OF MICRODOSE GnRH AGONIST PROTOCOL WITH GnRH ANTAGONIST/LETRAZOLE PROTOCOL IN PATIENTS WITH POOR OVARIAN RESPONSE. Türk Jinekoloji ve Obstetrik Derneği Dergisi, Cilt: 10 - Sayı: 3, 132–137. https://ajindex.com/articles/631528

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 2003; 9: 61- 76
  2. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul; 26(7): 1616- 24. Epub 2011 Apr 19
  3. Polyzos NP, Devroey P. A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel? Fertil Steril. 2011 Nov; 96(5): 1058- 61.e7
  4. Venetis CA, Kolibianakis EM, Tarlatzi TB, Tarlatzis BC. Evidence-based management of poor ovarian response. Ann N Y Acad Sci. 2010 Sep;1205: 199- 206. doi: 10.1111/j.1749- 6632.2010.05665.x. Review
  5. Kyrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril. 2009 Mar; 91(3): 749- 66. doi: 10.1016/j.fertnstert.2007.12.077. Epub 2008 Jul 21. Review
  6. Vollenhoven B, Osianlis T, Catt J. Is there an ideal stimulation regimen for IVF for poor responders and does it change with age? J Assist Reprod Genet. 2008 Nov-Dec; 25(11-12): 523- 9. doi: 10.1007/s10815-008-9274-6. Epub 2008 Nov 4
  7. Fábregues F, Peñarrubia J, Creus M, Manau D, Casals G, Carmona F, Balasch J. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Hum Reprod. 2009 Feb; 24(2): 349- 59. Epub 2008 Dec 3. 8. de Ziegler D, Streuli I, Meldrum DR, Chapron C. The value of growth hormone supplements in ART for poor ovarian responders. Fertil Steril. 2011 Nov; 96(5): 1069- 76
  8. Papanikolaou EG, Polyzos NP, Humaidan P, Pados G, Bosch E, Tournaye H, Tarlatzis B. Aromatase inhibitors in stimulated IVF cycles. Reprod Biol Endocrinol. 2011 Jun 21; 9: 85
  9. Jovanovic VP, Kort DH, Guarnaccia MM, Sauer MV, Lobo RA. Does the addition of clomiphene citrate or letrazole to gonadotropin treatment enhance the oocyte yield in poor responders undergoing IVF? J Assist Reprod Genet. 2011 Nov; 28(11): 1067- 72. Epub 2011 Oct 12
  10. Garcia-Velasco JA. The use of aromatase inhibitors in in vitro fertilization. Fertil Steril. 2012 Dec; 98(6): 1356- 8. doi: 10.1016/j.fertnstert.2012